Structure Optimization of 12β-O-γ-Glutamyl Oleanolic Acid Derivatives Resulting in Potent FXR Antagonist/Modulator for NASH Therapy. Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.